RU2000109595A - SYNERGICAL COMPOSITION AND METHODS FOR TREATING CONDITIONS OF NEOPLASTIC OR MALIGNANT GROWTH AND RESTORING OR ENHANCING HEMOPOESIS - Google Patents
SYNERGICAL COMPOSITION AND METHODS FOR TREATING CONDITIONS OF NEOPLASTIC OR MALIGNANT GROWTH AND RESTORING OR ENHANCING HEMOPOESISInfo
- Publication number
- RU2000109595A RU2000109595A RU2000109595/14A RU2000109595A RU2000109595A RU 2000109595 A RU2000109595 A RU 2000109595A RU 2000109595/14 A RU2000109595/14 A RU 2000109595/14A RU 2000109595 A RU2000109595 A RU 2000109595A RU 2000109595 A RU2000109595 A RU 2000109595A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- tumor
- cancer
- mutated
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 49
- 230000003211 malignant Effects 0.000 title claims 5
- 230000001613 neoplastic Effects 0.000 title claims 4
- 230000002708 enhancing Effects 0.000 title claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 230000000890 antigenic Effects 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 229920002359 Tetronic® Polymers 0.000 claims 12
- 239000000693 micelle Substances 0.000 claims 11
- 239000003921 oil Substances 0.000 claims 11
- 235000019198 oils Nutrition 0.000 claims 11
- 239000003599 detergent Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 8
- 230000001506 immunosuppresive Effects 0.000 claims 8
- 229920001983 poloxamer Polymers 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 210000002307 Prostate Anatomy 0.000 claims 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 5
- 230000003042 antagnostic Effects 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 230000003472 neutralizing Effects 0.000 claims 5
- 230000003071 parasitic Effects 0.000 claims 5
- 230000000087 stabilizing Effects 0.000 claims 5
- 241001631646 Papillomaviridae Species 0.000 claims 4
- 229960000502 Poloxamer Drugs 0.000 claims 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 4
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000000240 adjuvant Effects 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000007764 o/w emulsion Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229940032094 squalane Drugs 0.000 claims 4
- 230000003612 virological Effects 0.000 claims 4
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 claims 3
- 206010002368 Anger Diseases 0.000 claims 3
- 102100011431 BAGE Human genes 0.000 claims 3
- 108060000856 BAGE Proteins 0.000 claims 3
- 102000016736 Cyclins Human genes 0.000 claims 3
- 108050006400 Cyclins Proteins 0.000 claims 3
- 102100010782 EGFR Human genes 0.000 claims 3
- 101700039191 EGFR Proteins 0.000 claims 3
- 102100016662 ERBB2 Human genes 0.000 claims 3
- 101700025368 ERBB2 Proteins 0.000 claims 3
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims 3
- 102100004652 LGALS8 Human genes 0.000 claims 3
- 101710015832 LGALS8 Proteins 0.000 claims 3
- 102100012240 MGAT5 Human genes 0.000 claims 3
- 102100008857 MLANA Human genes 0.000 claims 3
- 101710012533 MLANA Proteins 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 229940051875 Mucins Drugs 0.000 claims 3
- 102000015728 Mucins Human genes 0.000 claims 3
- 108010063954 Mucins Proteins 0.000 claims 3
- AEMBWNDIEFEPTH-UHFFFAOYSA-N N-tert-butyl-N-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 3
- 102100009677 PWWP3A Human genes 0.000 claims 3
- 108060006838 PWWP3A Proteins 0.000 claims 3
- 208000003154 Papilloma Diseases 0.000 claims 3
- 101710037934 QRSL1 Proteins 0.000 claims 3
- 108091008153 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 208000001756 Virus Disease Diseases 0.000 claims 3
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 3
- 102000015735 beta Catenin Human genes 0.000 claims 3
- 108060000903 beta Catenin Proteins 0.000 claims 3
- 201000009030 carcinoma Diseases 0.000 claims 3
- 230000001419 dependent Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 244000045947 parasites Species 0.000 claims 3
- 101710029981 BLLF1 Proteins 0.000 claims 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Bute hydrocarbon Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 2
- 102000003425 EC 1.14.18.1 Human genes 0.000 claims 2
- 108060008724 EC 1.14.18.1 Proteins 0.000 claims 2
- 229920002046 Pluronic® L 62 LF Polymers 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 206010047461 Viral infection Diseases 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 230000011132 hemopoiesis Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 102000017186 transforming growth factor beta-activated receptor activity proteins Human genes 0.000 claims 2
- 108040009415 transforming growth factor beta-activated receptor activity proteins Proteins 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 102100008453 FOLH1 Human genes 0.000 claims 1
- 101700036477 FOLH1 Proteins 0.000 claims 1
- 108091006004 Fc-tagged proteins Proteins 0.000 claims 1
- 210000004907 Glands Anatomy 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006551 Parasitic Disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 229940068968 Polysorbate 80 Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 238000006065 biodegradation reaction Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- -1 eicosan Chemical compound 0.000 claims 1
- 230000029578 entry into host Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 230000003405 preventing Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- KMXFZRSJMDYPPG-UHFFFAOYSA-N tetratetracontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC KMXFZRSJMDYPPG-UHFFFAOYSA-N 0.000 claims 1
- 102000002938 thrombospondin family Human genes 0.000 claims 1
- 108060008245 thrombospondin family Proteins 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
Claims (1)
(а) смесь, включающую опухолевый, вирусный или паразитарный антиген, экспрессируемый указанными опухолевой, инфицированной вирусом или паразитом клетками, и микрофлюидизированную антигенную композицию, причем указанная антигенная композиция включает (i) стабилизирующий детергент, (ii) мицеллообразующий агент, и (iii) биологически разлагаемое и биологически совместимое масло, причем указанная антигенная композиция изготавливается в форме стабильной эмульсии масла в воде; и
(б) по меньшей мере один агент, который способен нейтрализовать или понижать активность иммуносупрессивных факторов.1. The composition comprising
(a) a mixture comprising a tumor, viral or parasitic antigen expressed by said tumor, virus or parasite infected cells, and a microfluidized antigenic composition, said antigenic composition comprising (i) a stabilizing detergent, (ii) a micelle forming agent, and (iii) biologically a degradable and biocompatible oil, wherein said antigenic composition is formulated as a stable oil in water emulsion; and
(b) at least one agent that is capable of neutralizing or lowering the activity of immunosuppressive factors.
18. Композиция по п. 1, в которой указанным агентом, способным нейтрализовать или понижать активность иммуносупрессивных факторов, секретируемых опухолью или организмом-хозяином, является анти-TGFβ антитело, ΤGFβR- слитый белок, аналог TGFβ, TGFβ- связывающий белок или TGFβR- блокирующее антитело.17. The composition of claim 1, wherein said immunosuppressive factor is TGFβ.
18. The composition according to claim 1, wherein said agent capable of neutralizing or lowering the activity of immunosuppressive factors secreted by a tumor or a host organism is an anti-TGFβ antibody, a ΤGFβR fusion protein, an analogue of TGFβ, TGFβ binding protein or TGFβR blocking antibody.
20. Композиция по п. 1, в которой указанная антигенная композиция включает сквалан, TWEEN 80 и полоксамер 401.19. The composition of claim 1, wherein said agent, capable of neutralizing or decreasing activity or preventing the activation of immunosuppressive factors secreted by a tumor or a host organism, is a thrombospondin peptide or TGFβR Fc-fusion protein.
20. The composition of claim 1, wherein said antigenic composition comprises squalane, TWEEN 80, and poloxamer 401.
25. Способ по п. 24, в котором указанные адъювант и антагонист вводят последовательно.24. The method of claim 23, wherein said secreted immunosuppressive factor is TGFβ.
25. The method of claim 24, wherein said adjuvant and antagonist are administered sequentially.
(а) смеси, включающей раковый или опухолевый антиген, экспрессируемый указанными малигнизированными клетками, и микрофлюидизированную антигенную композицию, причем указанная антигенная композиция включает (i) стабилизирующий детергент, (ii) мицеллообразующий агент, и (iii) биологически разлагаемое и биологически совместимое масло, указанная антигенная композиция изготавливается в форме стабильной эмульсии масла в воде, в котором указанная смесь вводится указанному пациенту в количестве, достаточном для индукции ответа цитотоксических Т-лимфоцитов у указанного пациента, который является специфичным в отношении указанного ракового или опухолевого антигена, содержащегося в указанной смеси, и
б) терапевтически эффективного количества по меньшей мере одного агента, который способен нейтрализовать или понижать активность иммуносупрессивных факторов, секретируемых опухолью или организмом-хозяином.32. A method of treating conditions of neoplastic or malignant growth, comprising administering to a patient in need thereof
(a) a mixture comprising a cancer or tumor antigen expressed by said malignant cells and a microfluidized antigenic composition, said antigenic composition comprising (i) a stabilizing detergent, (ii) a micelle forming agent, and (iii) a biodegradable and biocompatible oil, indicated the antigenic composition is made in the form of a stable oil-in-water emulsion in which the mixture is administered to the indicated patient in an amount sufficient to induce a cytotoxic T response lymphocytes in the specified patient, which is specific for the specified cancer or tumor antigen contained in the specified mixture, and
b) a therapeutically effective amount of at least one agent that is capable of neutralizing or lowering the activity of immunosuppressive factors secreted by the tumor or the host organism.
(а) смеси, включающей опухолевый, вирусный или паразитарный антиген, экспрессируемый указанными опухолевыми, инфицированными вирусами или паразитами клетками, и микрофлюидизированную антигенную композицию, причем указанная антигенная композиция включает (i) стабилизирующий детергент, (ii) мицеллообразующий агент, и (iii) биологически разлагаемое и биологически совместимое масло, причем указанная антигенная композиция изготавливается в форме стабильной эмульсии масла в воде, в котором указанная смесь вводится указанному пациенту в количестве, достаточном для индукции ответа цитотоксических Т-лимфоцитов у указанного пациента, который является специфичным в отношении вирусного или опухолевого антигена, содержащегося в указанной смеси, и
б) терапевтически эффективного количества по меньшей мере одного агента, способного нейтрализовать или понижать активность иммуносупрессивных факторов, секретируемых опухолью или организмом-хозяином, при котором указанную смесь и указанный агент вводят по отдельности или в комбинации, и в любом порядке.35. A method of recovering or enhancing hematopoiesis, comprising administering to a patient in need thereof
(a) a mixture comprising a tumor, viral or parasitic antigen expressed by said tumor, virus or parasite infected cells, and a microfluidized antigenic composition, said antigenic composition comprising (i) a stabilizing detergent, (ii) a micelle forming agent, and (iii) biologically a degradable and biocompatible oil, wherein said antigenic composition is made in the form of a stable oil-in-water emulsion in which said mixture is administered to a specified patient in a quantity stve sufficient to induce a cytotoxic T-lymphocytes in said patient which is specific for viral or tumor antigen contained in said mixture, and
b) a therapeutically effective amount of at least one agent capable of neutralizing or lowering the activity of immunosuppressive factors secreted by a tumor or a host organism, wherein said mixture and said agent are administered individually or in combination, and in any order.
(а) смесь, включающую опухолевый, вирусный или паразитарный антиген, экспрессируемый указанными опухолевой, инфицированной вирусом или паразитом клетками, и микрофлюидизированную антигенную композицию, причем указанная антигенная композиция включает (i) стабилизирующий детергент, (ii) мицеллообразующий агент, и (iii) биологически разлагаемое и биологически совместимое масло, причем указанная антигенная композиция изготавливается в форме стабильной эмульсии масла в воде; и
(б) один или несколько антагонистов TGFβ.37. Composition comprising
(a) a mixture comprising a tumor, viral or parasitic antigen expressed by said tumor, virus or parasite infected cells, and a microfluidized antigenic composition, said antigenic composition comprising (i) a stabilizing detergent, (ii) a micelle forming agent, and (iii) biologically a degradable and biocompatible oil, wherein said antigenic composition is formulated as a stable oil in water emulsion; and
(b) one or more TGFβ antagonists.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93335997A | 1997-09-18 | 1997-09-18 | |
US08/933,359 | 1997-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000109595A true RU2000109595A (en) | 2002-01-27 |
RU2219947C2 RU2219947C2 (en) | 2003-12-27 |
Family
ID=25463798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000109595/14A RU2219947C2 (en) | 1997-09-18 | 1998-09-17 | Synergetic composition and methods for treatment of states of neoplastic or malignant growth and recovery or enhancement of hemopoiesis |
Country Status (19)
Country | Link |
---|---|
US (4) | US20010018054A1 (en) |
EP (1) | EP1015031A4 (en) |
JP (1) | JP2001516727A (en) |
KR (1) | KR100540267B1 (en) |
CN (1) | CN1234413C (en) |
AR (1) | AR013012A1 (en) |
AU (1) | AU742216B2 (en) |
CA (1) | CA2303178A1 (en) |
CO (1) | CO4790100A1 (en) |
HK (1) | HK1033653A1 (en) |
IL (2) | IL134937A0 (en) |
IN (1) | IN190792B (en) |
MY (1) | MY131805A (en) |
NO (1) | NO20001413L (en) |
RU (1) | RU2219947C2 (en) |
SA (1) | SA98190719B1 (en) |
TW (1) | TWI252108B (en) |
WO (1) | WO1999013912A1 (en) |
ZA (1) | ZA988461B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197311B1 (en) * | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
AU2001247244B2 (en) * | 2000-02-28 | 2005-06-02 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
US7244232B2 (en) * | 2001-03-07 | 2007-07-17 | Biomed Solutions, Llc | Process for identifying cancerous and/or metastatic cells of a living organism |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US7491395B2 (en) | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
ATE490787T1 (en) | 2003-07-15 | 2010-12-15 | Chugai Pharmaceutical Co Ltd | PRODUCTION OF IGM BY TRANSFORMED CELLS AND METHOD FOR QUANTIFYING THIS IGM PRODUCTION |
US7981423B2 (en) | 2004-08-03 | 2011-07-19 | Transtech Pharma, Inc. | Rage fusion proteins |
US20090060925A1 (en) * | 2004-08-03 | 2009-03-05 | The Trustees Of Columbia University In The City Of | Rage Fusion Proteins and Methods of Use |
WO2007073272A1 (en) * | 2005-12-23 | 2007-06-28 | Gcoder Systems Ab | Positioning pattern |
BRPI0707640A2 (en) * | 2006-02-09 | 2011-05-10 | Transtech Pharma Inc | rage fusion proteins and methods of use |
WO2007130302A2 (en) * | 2006-05-05 | 2007-11-15 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
JP2011502964A (en) | 2007-10-23 | 2011-01-27 | ザ レジェンツ オブ ザ ユニバーシティ オブ コロラド | Competitive inhibitors of invariant chain expression and / or ectopic CLIP binding |
MX2011010989A (en) | 2009-04-20 | 2012-02-28 | Pfizer | Control of protein glycosylation and compositions and methods relating thereto. |
AU2010305374A1 (en) * | 2009-10-09 | 2012-05-03 | Sanofi | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
RU2018102375A (en) * | 2010-11-18 | 2019-02-21 | Зе Дженерал Хоспитал Корпорейшен | NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY |
WO2013078286A1 (en) * | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
US20150056199A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
KR20170054429A (en) | 2014-09-03 | 2017-05-17 | 제네세규스 인코포레이티드 | Therapeutic nanoparticles and related compositions, methods, and systems |
AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
MD3628049T2 (en) | 2017-05-04 | 2023-10-31 | Acceleron Pharma Inc | TGF-beta receptor type ii fusion proteins and uses thereof |
KR20200130709A (en) | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Prostate-specific membrane antigen CAR and methods of use thereof |
CN114814223A (en) * | 2022-04-20 | 2022-07-29 | 昆明市妇幼保健院 | System and equipment for monitoring and controlling plasmodium treatment |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052A (en) * | 1845-05-13 | Tktjss | ||
US20020004052A1 (en) * | 1990-05-08 | 2002-01-10 | David Berd | Composition comprising a tumor cell extract and method of using the composition |
US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
KR100198868B1 (en) * | 1991-07-25 | 1999-06-15 | 케네쓰 제이. 울코트 | Composition for the induction of cytotoxic t-lymphocyte responses |
US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
JPH08504763A (en) | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | Use of TGF-β receptor fragment as a therapeutic agent |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5932212A (en) | 1996-05-24 | 1999-08-03 | Altus Biologics, Inc. | Crosslinked protein crystal formulations and their use as catalysts in organic solvents |
-
1998
- 1998-09-16 ZA ZA988461A patent/ZA988461B/en unknown
- 1998-09-16 MY MYPI98004237A patent/MY131805A/en unknown
- 1998-09-17 AR ARP980104649A patent/AR013012A1/en not_active Application Discontinuation
- 1998-09-17 IL IL13493798A patent/IL134937A0/en not_active IP Right Cessation
- 1998-09-17 CA CA002303178A patent/CA2303178A1/en not_active Abandoned
- 1998-09-17 RU RU2000109595/14A patent/RU2219947C2/en not_active IP Right Cessation
- 1998-09-17 CO CO98053593A patent/CO4790100A1/en unknown
- 1998-09-17 EP EP98949313A patent/EP1015031A4/en not_active Withdrawn
- 1998-09-17 IN IN2797DE1998 patent/IN190792B/en unknown
- 1998-09-17 CN CNB988112809A patent/CN1234413C/en not_active Expired - Fee Related
- 1998-09-17 WO PCT/US1998/018495 patent/WO1999013912A1/en not_active Application Discontinuation
- 1998-09-17 AU AU95658/98A patent/AU742216B2/en not_active Ceased
- 1998-09-17 KR KR1020007002864A patent/KR100540267B1/en not_active IP Right Cessation
- 1998-09-17 JP JP2000511527A patent/JP2001516727A/en active Pending
- 1998-11-04 SA SA98190719A patent/SA98190719B1/en unknown
-
1999
- 1999-01-29 TW TW087115599A patent/TWI252108B/en not_active IP Right Cessation
-
2000
- 2000-03-07 IL IL134937A patent/IL134937A/en unknown
- 2000-03-17 NO NO20001413A patent/NO20001413L/en not_active Application Discontinuation
-
2001
- 2001-05-14 US US09/853,580 patent/US20010018054A1/en not_active Abandoned
- 2001-05-14 US US09/853,581 patent/US6998125B2/en not_active Expired - Lifetime
- 2001-06-19 HK HK01104231A patent/HK1033653A1/en not_active IP Right Cessation
-
2003
- 2003-12-24 US US10/743,739 patent/US20040137014A1/en not_active Abandoned
-
2005
- 2005-12-12 US US11/298,567 patent/US20060153848A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2219947C2 (en) | Synergetic composition and methods for treatment of states of neoplastic or malignant growth and recovery or enhancement of hemopoiesis | |
RU2000109595A (en) | SYNERGICAL COMPOSITION AND METHODS FOR TREATING CONDITIONS OF NEOPLASTIC OR MALIGNANT GROWTH AND RESTORING OR ENHANCING HEMOPOESIS | |
JP2001516727A5 (en) | ||
Cho et al. | BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses | |
Gerard et al. | Therapeutic potential of protein and adjuvant vaccinations on tumour growth | |
Neidhart et al. | Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor | |
Milani et al. | Recent advances in the development of breast cancer vaccines | |
KR100877759B1 (en) | Fusion protein for inhibiting cervical cancer | |
CA2533705A1 (en) | Use of liposomes in a water-in-oil emulsion or in a continuous hydrophobic carrier as a vehicle for cancer treatment | |
Foy et al. | Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor | |
KR20080091427A (en) | Concurrent chemotherapy and immunotherapy | |
Morris et al. | Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer | |
KR20200126334A (en) | Adjuvant for cancer immunotherapy | |
KR20170055550A (en) | Novel peptide and use thereof | |
JP2021533134A (en) | The adjuvant effect of the TLR1 / 2 agonist diprobossim, which shows a synergistic effect with the checkpoint inhibitory antibody and eliminates the disease. | |
RU93042874A (en) | POLYPEPTIDE NATURE COMPOUNDS, METHOD FOR THEIR PRODUCTION, A COMPOSITION ON THEIR BASIS, THEIR APPLICATION IN ANTI-CANCER THERAPY | |
Najar et al. | Topical CpG enhances the response of murine malignant melanoma to dacarbazine | |
Evans et al. | Vaccine therapy for cancer—fact or fiction? | |
EA200300638A1 (en) | VACCINE COMPOSITION CONTAINING A TRANSFORMING ALPHA GROWTH FACTOR | |
Naz et al. | Prophylactic vaccines for prevention of prostate cancer | |
Wolf et al. | Cytokines and cancer immunotherapy | |
Carson III et al. | Current immunotherapeutic strategies in breast cancer | |
Lollini et al. | Immunoprevention and immunotherapy of mammary carcinoma | |
US20220305105A1 (en) | Stabilized chimeric synthetic proteins and therapeutic uses thereof | |
Alfonso et al. | Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16 |